246 related articles for article (PubMed ID: 35095867)
21. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
22. Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-C.
Vollmers S; Lobermeyer A; Niehrs A; Fittje P; Indenbirken D; Nakel J; Virdi S; Brias S; Trenkner T; Sauer G; Peine S; Behrens GMN; Lehmann C; Meurer A; Pauli R; Postel N; Roider J; Scholten S; Spinner CD; Stephan C; Wolf E; Wyen C; Richert L; Norman PJ; Sauter J; Schmidt AH; Hoelzemer A; Altfeld M; Körner C
Front Immunol; 2022; 13():922252. PubMed ID: 35911762
[TBL] [Abstract][Full Text] [Related]
23. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A; Signorino E; Evangelista A; Brusa D; Mistrangelo M; Polimeni MA; Spadi R; Donadio M; Ciuffreda L; Matera L
J Transl Med; 2008 May; 6():25. PubMed ID: 18485193
[TBL] [Abstract][Full Text] [Related]
24. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
Arnould L; Gelly M; Penault-Llorca F; Benoit L; Bonnetain F; Migeon C; Cabaret V; Fermeaux V; Bertheau P; Garnier J; Jeannin JF; Coudert B
Br J Cancer; 2006 Jan; 94(2):259-67. PubMed ID: 16404427
[TBL] [Abstract][Full Text] [Related]
26. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling.
Stein MN; Shin J; Gudzowaty O; Bernstein AM; Liu JM
Anticancer Res; 2006; 26(3A):1759-63. PubMed ID: 16827104
[TBL] [Abstract][Full Text] [Related]
27. Influence of the immunogenetic KIR and HLA systems on long-term renal transplant outcome.
La Manna G; Corsini S; Iannelli S; Cappuccilli ML; Comai G; Iorio M; Todeschini P; Carretta E; Scolari MP; Bontadini A; Stefoni S
Ann Transplant; 2013 Nov; 18():611-21. PubMed ID: 24220609
[TBL] [Abstract][Full Text] [Related]
28. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
[TBL] [Abstract][Full Text] [Related]
29. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
30. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
31. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
Du R; Zhang X; Lu X; Ma X; Guo X; Shi C; Ren X; Ma X; He Y; Gao Y; Liu Y
Drug Resist Updat; 2023 May; 68():100947. PubMed ID: 36812747
[TBL] [Abstract][Full Text] [Related]
32. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
33. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
34. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
35. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
36. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
[TBL] [Abstract][Full Text] [Related]
37. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression.
Andersson S; Fauriat C; Malmberg JA; Ljunggren HG; Malmberg KJ
Blood; 2009 Jul; 114(1):95-104. PubMed ID: 19304956
[TBL] [Abstract][Full Text] [Related]
38. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
[TBL] [Abstract][Full Text] [Related]
39. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
40. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
